Mark C. Schneyer - 05 Apr 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, Chief Financial Officer
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
05 Apr 2022
Net transactions value
$0
Form type
4
Filing time
07 Apr 2022, 18:49:46 UTC
Previous filing
25 Feb 2022
Next filing
10 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Options (Right to Buy) Award $0 +72,414 $0.000000 72,414 05 Apr 2022 Common Stock 72,414 $25.75 Direct F1
transaction ACAD Restricted Stock Units Award $0 +21,101 $0.000000 21,101 05 Apr 2022 Common Stock 21,101 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on April 5, 2023. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.
F3 The restricted stock units vest in four equal annual installments beginning April 5, 2023.